ADGI Insider Trading Activity and SEC Form 4 Filings
ADGI insider trading summary
No open-market insider purchases or sales of Adagio Therapeutics, Inc. (ADGI) have been reported on SEC Form 4 in the past 12 months.
Latest ADGI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 1, 2022 | David Hering | Chief Executive Officer | Buy | $36K (8,000 @ $4.52) |
| Aug 19, 2022 | M28 Capital Management LP | Insider | Buy | $2.7M (584,451 @ $4.62) |
| Aug 19, 2022 | Marc Elia | Director | Buy | $2.7M (584,451 @ $4.62) |
| Aug 18, 2022 | M28 Capital Management LP | Insider | Buy | $5.5M (1,265,549 @ $4.31) |
| Aug 18, 2022 | Marc Elia | Director | Buy | $5.5M (1,265,549 @ $4.31) |
| Aug 17, 2022 | Marc Elia | Director | Buy | $4.0M (1,000,000 @ $4.04) |
| Aug 17, 2022 | M28 Capital Management LP | Insider | Buy | $4.0M (1,000,000 @ $4.04) |
| Aug 10, 2021 | Terrance McGuire | Director | Buy | $46K (2,678 @ $17.00) |
| Aug 10, 2021 | Terrance McGuire | Director | Buy | $89K (5,219 @ $17.00) |
| Aug 10, 2021 | Terrance McGuire | Director | Buy | $4.6M (267,769 @ $17.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.